Are age and anti-Müllerian hormone good predictors of ovarian reserve and response in women undergoing IVF?

Abstract

ObjectiveOvarian reserve evaluation has been the focus of substantial clinical research for several years. This study aimed to examine the associations between markers of ovarian reserve and ovarian response.MethodsThis prospective study included 132 infertile women aged 24-48 years undergoing routine exploration during unstimulated cycles prior to the start of assisted reproductive technology (ART) treatments at our center from July 2015 to January 2017. Descriptive parameters and patient characteristics were reported as mean (SD) or median (range) values depending on the data distribution pattern. Student’s t-test was performed for continuous variables; the Wilcoxon and Pearson’s test were used for data not following a normal distribution; and Fisher’s test was used for categorical variables. p<0.05 was considered statistically significant.ResultsAt the time of the study, the patients had a mean age of 35.7±3.84 years. On day 3 of the cycle, the mean anti-Müllerian hormone (AMH) serum level was 2.84±1.57 ng/mL and the patients had 14.68±4.2 antral follicles (AFC). A significant correlation was observed between AMH and age (r=-0.34 p<.01), follicle stimulating hormone (FSH) serum levels (r=-0.32, p<.01), AFC (r=0.81, p<.00001), total dose of medication during ovarian stimulation (r=-0.28, p<.0003), and ongoing pregnancy rate (p<.05). Age was significantly correlated with FSH (r=0.46, p<.01), AFC (r=-0.34, p<.00001), total dose of medication during ovarian stimulation (r=0.43, p<.0003), and ongoing pregnancy rate (p<.04).ConclusionSerum AMH and age are independent predictors of ovarian reserve and ovarian stimulation outcome in infertile women. Age and serum AMH level may be used to advise subfertile couples of their pregnancy prospects.

Anti‐Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4

“…20 However, few studies have assessed the ability of AFC to predict IVF outcomes in poor responders. 11,21,22 In addition, because AMH is generally accepted as being one of the most reliable biomarkers for assessing ovarian reserve and predicting ovarian response in terms of the number of oocytes retrieved, 20,21,[23][24][25] the association of AMH with qualitative outcomes after assisted conception, especially the live birth, which is the ultimate outcome of assisted conception, has attracted considerable attention. 9,10,12,15,16,19,26 However, the reported findings have been conflicting and the association between AMH and live birth remains unclear.…”

The relationship between anti-Müllerian hormone (AMH) levels and pregnancy outcomes in patients undergoing assisted reproductive techniques (ART)

“…Most women are unaware that fertility starts to decline after the early thirties in some individuals. With increasing female age, fecundity in natural and stimulated ovarian cycles declines, as observed in population-based studies (Grynnerup, Lindhard & Sorensen, 2012) as well as in IVF studies (Scheffer et al, 2018). For this reason, there is a growing number of women of advanced age seeking treatment for infertility (Oskayli et al, 2019).…”

Peer Review #2 of "The relationship between anti-Müllerian hormone (AMH) levels and pregnancy outcomes in patients undergoing assisted reproductive techniques (ART) (v0.1)"

“…Most women are unaware that fertility starts to decline after the early thirties in some individuals. With increasing female age, fecundity in natural and stimulated ovarian cycles declines, as observed in population-based studies (Grynnerup et al, 2012) as well as in IVF studies (Scheffer et al, 2018). For this reason, there is a growing number of women of advanced age seeking treatment for infertility (Oskayli et al, 2019).…”